An observational study in Fatigue Post Viral, sponsored by University Hospital, Akershus. Recruiting at 1 site in Norway. Open to participants aged 16 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by University Hospital, Akershus · Observational
Persistent fatigue (PF) is a common symptom across countries and cultures, and an important cause of disability and reduced quality of life. Acute infection is a common trigger of PF, as exemplified by the 'Long COVID' phenomenon. Despite substantial burden for the suffering individuals as well as their next-of-kins, the healthcare systems and the economy, PF is an under-researched field, with scarce knowledge of disease mechanisms as well as treatment and preventive measures.
Existing knowledge on PF suggests complex interactions between functional brain processes (as opposed to permanent brain damage), aberrations of the immune system (that normally protects against infection) and the autonomic (or non-voluntary) part of the nervous system (that monitors the internal state of the body and adjusts the function of internal organs). Previous findings have been interpreted in light of two alternative models: A body-to-brain mechanism where disturbances of the immune system are thought to impact on brain functions, and a brain-to-body mechanism where functional brain alteration is regarded the central element whereas aberration of the immune system is seen as a consequence (rather than a cause) mediated through altered activity of the autonomic nervous system.
The multinational and collaborative Mechanism of Persistent Fatigue (MAP-FAT) project is determined to scrutinize both these potential brain-body interactions in PF. The main objectives are: a) To determine the relationship between PF, activities in certain brain areas, activity in a certain part of the autonomic nervous system (the sympathetic branch), and immunological alterations; b) To determine whether PF is primarily dependent upon the brain's automatic predictions rather than the continuous sensory information mediated to the brain. To achieve these objectives, MAP-FAT will exploit an existing health registry on post-infective fatigue (preparatory part) and conduct a new post-infective cohort study (main part) in which a total of 150 individuals with "kissing disease" and 150 healthy controls are followed for six months. Investigations include: a) Clinical and demographic assessment; b) Questionnaire charting; c) Functional and structural imaging of the brain (multimodal brain MRI); d) Assessment of autonomic nervous system activity; e) Deep immunological profiling; and f) Behavioral experiments. The latter are specifically designed to disentangle the relative contributions of the brain's automatic predictions and sensory input for the experience of PF. In addition, one of the experiments includes concurrent functional brain imaging, autonomic nervous system assessment, and immunological profiling during experimental injections of drugs that impact on autonomic activity; this experiment is key for addressing the causal association between brain functions, autonomic activity and immunological disturbance.
2,229 studies on the registry are indexed under Fatigue; 426 are open to participants now.
This study's planned enrollment of 300 is above the median of 99 across 406 observational studies indexed under Fatigue.
Browse Fatigue studies →University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 28 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The population served by the South-Eastern Norway Regional Health Authority (approximately 3.1M)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (pertaining to both groups)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Individuals with acute Epstein-Barr virus infection
Healthy control individuals (ie., no acute EBV infection)
ASP difference
The difference in symptom ratings between neutral and negative affect provoking pictures during the Affect and Symptom Paradigm (ASP)
Time frame: At six months' follow-up
VHBP regression ratio
Ratio between the regression coefficient for exerted power vs. fatigue (an index of interoceptive input) and the regression coefficient for virtual hill gradient vs. fatigue (an index of prior expectations) during the Virtual Hill Bicycling Paradigm (VHBP)
Time frame: At six months' follow-up
INSULA connectivity
Functional connectivity characteristics of the Insula cortical brain region
Time frame: At six months' follow-up
FATIGUE CFQ
Fatigue scores (sum score from the Chalder Fatigue Questionnaire (CFQ), where higher values means more fatigue).
Time frame: At six months' follow-up
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized IPD from all elements of MAP-FAT will be shared at a trusted, public repository such as ZENODO. We will adhere to the FAIR (findable, accessible, interoperable, reusable) principles: A unique and persistent Digital Object Identifier (DOI) will be assigned to each item in the public repository, thus making them easily findable. MAP-FAT (meta)data will be retrievable by its identifier; all beneficiaries will ensure open access to the deposited data, following the principle 'as open as possible as closed as necessary'. MAP-FAT (meta)data will use a formal, accessible, shared, and broadly applicable language for knowledge representation. Interoperability resources such as FAIRsharing will be applied. The conditions under which the data can be used will be made transparent through easy-to-use copyright licenses, such as Creative Commons (Creative Commons Attribution International Public License, CC BY) or Creative Commons Public Domain Dedication (CC 0).
Supporting information: Study protocol, Statistical analysis plan
Time frame: Start date: six monhts after last patient to follow-up (anticipated Oct 2027) End date: After five years
Access criteria: Cf. above. Anonymized data will be shared at a public repository. Data will be made available for scientific purposes upon request.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Akershus →